{"id":240399,"date":"2018-07-12T06:35:04","date_gmt":"2018-07-12T06:35:04","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=240399"},"modified":"2018-07-12T06:35:04","modified_gmt":"2018-07-12T06:35:04","slug":"global-pd1-pdl1-pipeline-analysis-2018-market-size-development-status-type-and-application-segmentation-forecast","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/global-pd1-pdl1-pipeline-analysis-2018-market-size-development-status-type-and-application-segmentation-forecast_240399.html","title":{"rendered":"Global PD-1 &#038; PD-L1 Pipeline Analysis 2018 Market Size, Development Status, Type and Application, Segmentation, Forecast"},"content":{"rendered":"<div style=\" width:250px; padding:8px 10px 10px 10px; float:right;\"><a href=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2018\/07\/1435889040.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"image\" src=\"http:\/\/www.abnewswire.com\/pressreleases\/wp-content\/uploads\/2018\/07\/1435889040.png\" alt=\"\" width=\"225\" height=\"\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\" style=\" font-weight:bold; font-style:italic;\">\n<div>&#8220;\\&#8221;PD-1 &#038; PD-L1 Market\\&#8221;&#8221;<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">WiseGuyReports.com adds \u201cPD-1 &#038; PD-L1 Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting\u201d reports to its database.<\/div>\n<p><strong><a rel=\"nofollow\" href=\"https:\/\/www.wiseguyreports.com\/sample-request\/3271726-pd-1-pd-l1-pipeline-analysis-2018\">PD-1 &amp; PD-L1 Market<\/a><\/strong><strong>:<\/strong><\/p>\n<p><strong>Executive Summary<\/strong><\/p>\n<p>Adroit Healthcare Services provide the comprehensive list of PD-1 and PD-L1 antibodies that are marketed for different indications and the products that are in development. The main objective of this report is to provide a comprehensive secondary research and market analysis of anti-CD19 antibody pipeline products that are in Phase 3, Phase 2, Phase 1, preclinical and discovery across different indications. This report also provides comprehensive research on the companies that are working on anti-CD19 antibody including the deals and acquisitions.<\/p>\n<p><strong>Report Coverage: <\/strong><\/p>\n<ul>\n<li>Clinical (Phase Products)<\/li>\n<li>Non-clinical (Preclinical and Discovery)<\/li>\n<li>Dormant and Discontinued<\/li>\n<li>Technology<\/li>\n<li>Collaboration details<\/li>\n<\/ul>\n<p><strong>Companies Mentioned<\/strong><\/p>\n<p>Bristol-Myers Squibb, Merck &amp; Co., CureTech, AstraZeneca, ImmunOs Therapeutics, Regeneron Pharmaceuticals, Novartis Pharmaceuticals,<\/p>\n<p><strong>Request Sample Report @ <a rel=\"nofollow\" href=\"https:\/\/www.wiseguyreports.com\/sample-request\/3271726-pd-1-pd-l1-pipeline-analysis-2018\">https:\/\/www.wiseguyreports.com\/sample-request\/3271726-pd-1-pd-l1-pipeline-analysis-2018<\/a> <\/strong><\/p>\n<p><strong>Table of Content:<\/strong><\/p>\n<p>Executive Summary<\/p>\n<p>Programmed Death 1 (PD-1)<\/p>\n<p>Programmed Death Ligand 1 (PD-L1)<\/p>\n<ul>\n<li>Description and MOA of PD-1 and PD-L1 pathways<\/li>\n<li>Significance of PD-1 and PD-L1 inhibitors<\/li>\n<li>Therapy Areas related to PD-1 and PD-L1<\/li>\n<li>Biomarkers &#8211; PD-1 and PD-L1 inhibitors<\/li>\n<\/ul>\n<p>Competitive Landscape<\/p>\n<ul>\n<li>Market Overview<\/li>\n<li>Marketed Drug Candidate Profiles<\/li>\n<li>Marketed Drugs Sales<\/li>\n<li>Details of Patent Expiry of Marketed Drugs<\/li>\n<\/ul>\n<p>Current and Future Market for PD and PD-L1 inhibitors<\/p>\n<p>Challenges and Barriers associated with use of PD and PD-L1 inhibitors<\/p>\n<p>PD-1\/PD-L1 Combinations Profiles<\/p>\n<p>Pipeline Therapeutics<\/p>\n<p>Therapeutics under Development by Companies<\/p>\n<p>Late State Products<\/p>\n<ul>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p>Mid Stage Products<\/p>\n<ul>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p>Early Stage Products<\/p>\n<ul>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p>Preclinical &amp; Discovery<\/p>\n<ul>\n<li>Product Description<\/li>\n<li>Research and Development<\/li>\n<li>Product Development Activities<\/li>\n<\/ul>\n<p>Therapeutic Assessment<\/p>\n<ul>\n<li>Assessment by Route of Administration<\/li>\n<li>Assessment by Phase &amp; Route of Administration<\/li>\n<li>Assessment by Molecule Type<\/li>\n<li>Assessment by Phase &amp; Molecule type<\/li>\n<\/ul>\n<p>Collaborations and Acquisitions Details<\/p>\n<p>Dormant Products<\/p>\n<p>Discontinued Products<\/p>\n<p>Appendix<\/p>\n<p>Methodology<\/p>\n<p>Disclaimer<\/p>\n<p>Table 1: Marketed and Pipeline PD-1 and PD-L1 drugs, 2018<\/p>\n<p>Table 2: Sales of Marketed drugs, 2018<\/p>\n<p>Table 3: Patent expiration details &ndash; marketed drugs, 2018<\/p>\n<p>Table 4: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2018<\/p>\n<p>Table 5: Products under Development by Companies, 2018<\/p>\n<p>Table 6: Late Stage Products, 2018<\/p>\n<p>Table 7: Mid Stage Products, 2018<\/p>\n<p>Table 8: Early Stage Products, 2018<\/p>\n<p>Table 9: Pre-Clinical and Discovery Products, 2018<\/p>\n<p>Table 10: Assessment by Route of Administration, 2018<\/p>\n<p>Table 11: Assessment by Stage and Route of Administration, 2018<\/p>\n<p>Table 12: Assessment by Molecule Type, 2018<\/p>\n<p>Table 13: Assessment by Stage and Molecule Type, 2018<\/p>\n<p>Table 14: Comparative Analysis<\/p>\n<p>Table 15: Dormant Products<\/p>\n<p>Table 16: Discontinued Products<\/p>\n<p>Figure 1: Marketed and Pipeline PD-1 and PD-L1 drugs, 2018<\/p>\n<p>Figure 2: Sales of Marketed drugs, 2018<\/p>\n<p>Figure 3: Patent expiration details &ndash; marketed drugs, 2018<\/p>\n<p>Figure 4: Number of Products Under Development for PD-1 and PD-L1 inhibitors Drugs, 2018<\/p>\n<p>Figure 5: Products under Development by Companies, 2018<\/p>\n<p>Figure 6: Late Stage Products, 2018<\/p>\n<p>Figure 7: Mid Stage Products, 2018<\/p>\n<p>Figure 8: Early Stage Products, 2018<\/p>\n<p>Figure 9: Pre-Clinical and Discovery Products, 2018<\/p>\n<p>Figure 10: Assessment by Route of Administration, 2018<\/p>\n<p>Figure 11: Assessment by Stage and Route of Administration, 2018<\/p>\n<p>Figure 12: Assessment by Molecule Type, 2018<\/p>\n<p>Figure 13: Assessment by Stage and Molecule Type, 2018<\/p>\n<p>Figure 14: Comparative Analysis<\/p>\n<p>Figure 15: Dormant Products<\/p>\n<p>Figure 16: Discontinued Products<\/p>\n<p><strong>Continuous&hellip;<\/strong><\/p>\n<p><strong>For further information on this report, visit &ndash;<\/strong> <strong><a rel=\"nofollow\" href=\"https:\/\/www.wiseguyreports.com\/reports\/3271726-pd-1-pd-l1-pipeline-analysis-2018\">https:\/\/www.wiseguyreports.com\/reports\/3271726-pd-1-pd-l1-pipeline-analysis-2018<\/a><\/strong><\/p>\n<p>&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> Wiseguyreports.com<br \/><strong>Contact Person:<\/strong> Norah Trent<br \/><strong>Email:<\/strong> <a href='http:\/\/www.universalpressrelease.com\/?pr=global-pd1-pdl1-pipeline-analysis-2018-market-size-development-status-type-and-application-segmentation-forecast&#038;type=pra'>Send Email<\/a><br \/><strong>Phone:<\/strong> +1 646 845 9349, +44 208 133 9349<br \/><strong>City:<\/strong> Pune<br \/><strong>State:<\/strong> Maharashtra<br \/><strong>Country:<\/strong> India<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.wiseguyreports.com\" target=\"_blank\" rel=\"nofollow\">www.wiseguyreports.com<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.wiseguyreports.com\" style=\"width:605px; height:400px;\"><\/object><\/p>\n<p><img decoding=\"async\" src=\"http:\/\/www.abnewswire.com\/press_stat.php?pr=global-pd1-pdl1-pipeline-analysis-2018-market-size-development-status-type-and-application-segmentation-forecast\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;\\&#8221;PD-1 &#038; PD-L1 Market\\&#8221;&#8221; WiseGuyReports.com adds \u201cPD-1 &#038; PD-L1 Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting\u201d reports to its database. PD-1 &amp; PD-L1 Market: Executive Summary Adroit Healthcare Services provide the comprehensive list of PD-1 and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/global-pd1-pdl1-pipeline-analysis-2018-market-size-development-status-type-and-application-segmentation-forecast_240399.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-240399","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/240399","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=240399"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/240399\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=240399"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=240399"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=240399"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}